NLC1A: A Potential Drug Target for Cancer (G727699)

Target Name: LINC00163

NCBI ID: G727699

LINC00163

NLC1A: A Potential Drug Target for Cancer

LINC00163 (NLC1A) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study and develop new treatments.

The NLC1A molecule is a single RNA molecule that is approximately 200 nucleotides long. It is expressed in most tissues and cells of the body and is involved in various cellular processes, including cell growth, differentiation, and RNA processing. One of the most interesting aspects of NLC1A is its ability to interact with other molecules and proteins.

One of the key features of NLC1A is its ability to interact with the protein encoded by the gene SCL/TAL1. This protein is known for its role in regulating cell growth and is often associated with the development of cancer. By interacting with SCL/TAL1, NLC1A has been shown to regulate the activity of this protein and influence the growth and survival of various cell types.

Another interesting aspect of NLC1A is its ability to interact with the protein encoded by the gene PDGFRA. PDGFRA is a protein that is involved in the development and maintenance of tissues and organs, and is often associated with the development of cancer. By interacting with PDGFRA, NLC1A has been shown to regulate the activity of this protein and influence the growth and survival of various cell types.

In addition to its interactions with SCL/TAL1 and PDGFRA, NLC1A has also been shown to interact with a variety of other proteins and molecules. These interactions have important implications for the function of NLC1A and its potential as a drug target.

The potential benefits of targeting NLC1A as a drug target are numerous. By inhibiting the activity of NLC1A, researchers can reduce the growth and survival of cancer cells and potentially lead to the development of new treatments for cancer. Additionally, NLC1A has been shown to play a role in the development and maintenance of various tissues and organs, which makes it an attractive target for drugs that are designed to promote tissue repair and regeneration.

In conclusion, LINC00163 (NLC1A) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study and develop new treatments. As more research is conducted on NLC1A, it is likely that new treatments for cancer and other diseases will be developed.

Protein Name: Long Intergenic Non-protein Coding RNA 163

The "LINC00163 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00163 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets